Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock

Lynne Marie Sullivan, the Chief Financial Officer and Head of Corporate Development at Unity Biotechnology, Inc. (NASDAQ:UBX), recently sold 21,867 shares of the company’s common stock. The transaction, which took place on April 2, 2025, was valued at approximately $22,523, with shares sold at a price of $1.03 each. The micro-cap biotech company, currently valued at $16.61 million, has seen its shares decline over 10% in the past week, now trading near its 52-week low of $0.94. InvestingPro analysis suggests the stock is currently trading below its Fair Value.

According to the filing, the sale was made to cover tax withholding obligations related to the vesting of Restricted Stock Units. Following this transaction, Sullivan retains ownership of 98,905 shares of Unity Biotechnology, which includes additional Restricted Stock Units that will vest over time. With an overall Financial Health score of FAIR according to InvestingPro, which offers 8 additional key insights about UBX’s financial position and market performance, investors can access comprehensive analysis to make informed decisions.

In other recent news, Unity Biotechnology announced the results from its Phase 2b ASPIRE study for UBX1325, a treatment for diabetic macular edema (DME). Although the study did not meet its primary endpoint at weeks 20 and 24, UBX1325 showed non-inferiority to aflibercept at nine out of ten time points over a 36-week period. Mizuho (NYSE:MFG) Securities maintained its Outperform rating with a $6.00 price target, while H.C. Wainwright reduced its target to $4.00 but kept a Buy rating. Chardan Capital Markets initiated coverage with a Buy rating and a $6.00 price target, emphasizing the potential of UBX1325’s novel mechanism.

Additionally, Unity Biotechnology appointed Federico Grossi, M.D., Ph.D., as the new chief medical officer, bringing significant experience in clinical development and regulatory strategy. The company is set to release the complete 36-week data in the coming months, which will inform future clinical studies. Unity’s UBX1325 is being developed as a potential treatment option for patients who have not responded to existing therapies. The company remains focused on advancing its therapeutic portfolio, particularly in age-related diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.